Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma：An Open-Label, Single-center, Single-arm Study

NCT03383237 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT03383237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03383237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma：An Open-Label, Single-center, Single-arm Study
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
November 29, 2017
Completion date
November 30, 2019
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma